AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11455374
Drug: Antimicrobial varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial varnish in combination with fluoride varnish (group 1)
Trial: 11455374
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antimicrobial and fluoride varnishes
Trial: 9543133
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day, n = 16)
Trial: 9543133
Drug: Toremifene (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (40 mg/day, n = 14)
Trial: 2726331
Drug: Schedule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A (10 micrograms of hepatitis B vaccine at 0, 1, 2, and 11 months)
Trial: 2726331
Drug: Schedule B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B (10 micrograms of hepatitis B vaccine at 3, 4, 5, and 11 months)
Trial: 14608552
Drug: Routine nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine nursing care treatment (control group)
Trial: 1578079
Drug: UV‐A condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV‐A condition (light therapy with UV-A wavelengths)
Trial: 1578079
Drug: UV-blocked condition
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-blocked condition (light therapy without UV-A wavelengths)
Trial: 3933645
Drug: Methylprednisolone pulses
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulses followed by low dose oral prednisone for six months
Trial: 3933645
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral prednisone for four weeks followed by low dose oral prednisone for five months
Trial: 18001250
Drug: Bromfenac ophthalmic
RxNorm normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac ophthalmic solution 0.09%
Trial: 27531286
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (dexamethasone 0.1% and tobramycin 0.3%) alone
Trial: 22335395
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention consisting of self‐monitored blood pressure, medicine review, a Digital Versatile Disc, and motivational interviewing telephone calls over 3 months.
Trial: 20003697
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (MXF) 400 mg daily for the first 2 months
Trial: 20003697
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen plus daily 400 mg MXF
Trial: 7477192
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (t‐PA)
Trial: 30607782
Drug: Omega-3 long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 long chain polyunsaturated fatty acids (722 mg docosahexaenoic acid)
Trial: 30607782
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 IU daily)
Trial: 25443863
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) - single session
Trial: 21150467
Drug: Irinotecan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (50 mg/m on days 1, 8, and 15) plus paclitaxel (180 mg/m on day 1) every 4 weeks (IP group)
Trial: 21150467
Drug: Irinotecan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (100 mg/m on days 1 and 8) plus gemcitabine (1000 mg/m on days 1 and 8) every 3 weeks (IG group)
Trial: 2595103
Drug: NaHCO3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (300 mg/kg body weight)
Trial: 2595103
Drug: CaCO3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 (300 mg/kg body weight)
Trial: 4933388
Drug: DEAE Sephadex
RxNorm normalized name: DEAE-rebeccamycin
DrugBank: Becatecarin (DB06362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEAE Sephadex (12‐15 g/day)
Trial: 9866536
Drug: Blood sampling
RxNorm normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood sampling from peripheral intravenous infusion lines
Trial: 7715904
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron i.v. + placebo p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Trial: 7715904
Drug: Placebo i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. + 8 mg ondansetron p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Trial: 7715904
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg granisetron i.v. + placebo p.o. before chemotherapy + placebo p.o. b.d. until day 5
Trial: 2462067
Drug: Luteinizing hormone‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone‐releasing hormone agonist buserelin
Trial: 880971
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg b.i.d. for 3 weeks and 200 mg b.i.d. for 3 weeks)
Trial: 30300021
Drug: Combined laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined laser with topical photo‐enhancer gel
Trial: 30300021
Drug: Solo laser
RxNorm normalized name: Fallback Solo
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solo laser treatment
Trial: 29029097
Drug: Control (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (lower doses)
Trial: 25892658
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (.08 mg/kg)
Trial: 23356494
Drug: Intravenous iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iloprost after liver transplantation
Trial: 21904779
Drug: Pentazocine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (0.3 mg/kg)
Trial: 18673303
Drug: Aerobic Interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic Interval Training (AIT) - 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
Trial: 18673303
Drug: Multidisciplinary Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary Treatment Group (MTG) - exercise, dietary and psychological advice, twice a month for 12 months
Trial: 18673303
Drug: Multidisciplinary Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary Treatment Group (MTG)
Trial: 15223085
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 100 mg QD (increased to 200 mg QD after 1 week, with further increases allowed up to 400 mg QD)
Trial: 30519976
Drug: General practitioner‐led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner‐led interprofessional medication assessment
Trial: 28349727
Drug: β‐alanine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐alanine group (6.4 g day‐1 of β‐alanine)
Trial: 28349727
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (6.4 g day‐1 of dextrose)
Trial: 23065656
Drug: Enzastaurin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (500 mg daily for 6 months)
Trial: 17153886
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) with standardized P sylvestris pollen extract
Trial: 14969156
Drug: Nitroglycerin 15
RxNorm normalized name: NITROGLYCERIN 15MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 15 mg in slow-release form (N-15)
Trial: 10928427
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone gel, 90 mg
Trial: 10711552
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) progesterone, 50 mg
Trial: 23294143
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges containing L. reuteri (ATCC55730 and ATCC PTA5289) taken twice a day
Trial: 23294143
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges taken twice a day
Trial: 11240881
Drug: Ondansetron 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.04 mg.kg‐1 (1 mg.m‐2)
Trial: 11240881
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg.kg‐1 (2.5 mg.m‐2)
Trial: 11240881
Drug: Ondansetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.2 mg.kg‐1 (5 mg.m‐2)
Trial: 11240881
Drug: Overall Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overall Ondansetron (all doses)
Trial: 3555055
Drug: Single-dose ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ciprofloxacin (500 mg)
Trial: 3555055
Drug: Three-day ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-day ciprofloxacin (500 mg twice daily)
Trial: 3555055
Drug: Three-day trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively, twice daily)
Trial: 24991787
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of statins
Trial: 23690531
Drug: Sulfonylureas, Dipeptidyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Insulin (added to metformin 1,000-2,000 mg/day)
Trial: 18836692
Drug: Calcium ascorbate
RxNorm normalized name: Calcium Ascorbate
DrugBank: Calcium ascorbate (DB14483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium ascorbate with vitamin C metabolites (two formulations)
Trial: 16415712
Drug: Intravenous clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clomipramine (CMI) 150 mg on day 1 and 200 mg on day 2, followed by oral CMI starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Trial: 16415712
Drug: Oral clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clomipramine (CMI) starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Trial: 3161529
Drug: Midazolam; repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam; repeated doses
Trial: 3161529
Drug: Diazepam; similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam; similar doses given with the same frequency
Trial: 28474984
Drug: CO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO inhalation (carboxyhemoglobin 22%)
Trial: 21262673
Drug: Non-adjuvanted inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted inactivated fungal vaccine
Trial: 18853114
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional treatment)
Trial: 12737092
Drug: Neurofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback treatment (3-month electroencephalographic feedback program providing reinforcement contingent on the production of cortical sensorimotor rhythm (12-15 Hz) and beta activity (15-18 Hz))
Trial: 17714375
Drug: Methylphenidate (stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (stimulant medication)
Trial: 10471981
Drug: Tegaserod (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (12 mg oral dose) administered 30 minutes prior to meal
Trial: 10471981
Drug: Tegaserod (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (12 mg oral dose) administered 15 minutes prior to meal
Trial: 10471981
Drug: Tegaserod (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (12 mg oral dose) administered 1 minute before meal
Trial: 10471981
Drug: Tegaserod (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (12 mg oral dose) administered 2.5 hours after meal
Trial: 10471981
Drug: Tegaserod (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (12 mg oral dose) administered with a continued 4-hour postdose fast
Trial: 1332526
Drug: No Treatment
RxNorm normalized name: NO
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Treatment (NT) condition
Trial: 31764900
Drug: Natural food-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural food-based fiber solution
Trial: 22370992
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of arachidonic acid (ARA) added to docosahexaenoic acid (DHA) (n = 7)
Trial: 20200197
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta-1a
Trial: 15644650
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 6 mL/kg predicted body weight
Trial: 15644650
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 12 mL/kg predicted body weight
Trial: 11824860
Drug: Isotonic volume
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic volume contraction (induced by furosemide infusion and replaced by 5% isotonic glucose infusion)
Trial: 1588979
Drug: Inhaled methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled methoxamine (10 mg)
Trial: 1963135
Drug: Isotretinoin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (10 mg)
Trial: 6291889
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg IV bolus)
Trial: 6291889
Drug: Cimetidine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (0.12 mg/ml in vitro)
Trial: 6291889
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg over 12 hours)
Trial: 6291889
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg IV bolus)
Trial: 6291889
Drug: Ranitidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (100 mg IV bolus)
Trial: 30019768
Drug: Active learning
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active learning education program (weekly 90‐minute sessions for 24 weeks)
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 1 mg with 200 mg 5-CNAC
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 2.5 mg with 200 mg 5-CNAC
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 5 mg with 200 mg 5-CNAC
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 10 mg with 200 mg 5-CNAC
Trial: 22289659
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg sc
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 2.5 mg with 100 mg 5-CNAC
Trial: 22289659
Drug: Oral PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PTH134 5 mg with 100 mg 5-CNAC
Trial: 20584172
Drug: sFas levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sFas levels in overweight/obese men (2.42 ng mL(‐1))
Trial: 20584172
Drug: sFas levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sFas levels in men with hyperlipidaemia (2.34 ng mL(‐1))
Trial: 681526
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment strategies
Trial: 25996534
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid application after PELD
Trial: 25996534
Drug: Saline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline treatment after PELD
Trial: 16426098
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to first treatment
Trial: 16426098
Drug: Recommendations for
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations for treatment outcome data acquisition
Trial: 15232328
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 60 mg/d)
Trial: 15232328
Drug: Testosterone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (up to 400 mg IM testosterone cypionate biweekly)
Trial: 9205633
Drug: etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etidronate 400 mg/day
Trial: 8094485
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of 0.3‐0.5 ml sterile water
Trial: 2959717
Drug: rt-PA (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (0.75 mg/kg)
Trial: 2959717
Drug: rt-PA (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (40 or 80 mg)
Trial: 2959717
Drug: single chain
RxNorm normalized name: Single chain urokinase-like plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single chain rt-PA (100 mg total)
Trial: 29792839
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (ibuprofen 800 mg orally, lidocaine paracervical block, anticipatory guidance)
Trial: 25894960
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate treatment (group 1)
Trial: 16083195
Drug: Thai-made levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thai-made levonorgestrel pill (0.75 mg)
Trial: 16083195
Drug: Hungarian levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hungarian levonorgestrel pill (0.75 mg)
Trial: 9401829
Drug: Lubeluzole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 2.5 mg
Trial: 9401829
Drug: Lubeluzole 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 5 mg
Trial: 9401829
Drug: Lubeluzole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 10 mg
Trial: 9401829
Drug: Lubeluzole 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 15 mg
Trial: 9401829
Drug: Lubeluzole 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 20 mg
Trial: 9401829
Drug: Lubeluzole 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 25 mg
Trial: 8099593
Drug: Cetirizine, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 15 mg twice daily
Trial: 3543236
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (high-dose methotrexate, Adriamycin, BCD)
Trial: 2840035
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy (control group)
Trial: 22883272
Drug: Puerarin Injection
RxNorm normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin Injection
Trial: 22883272
Drug: Danshen Injection
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen Injection
Trial: 18657196
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin mix 50
Trial: 9862296
Drug: Continuous ultrasound
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ultrasound therapy at 1.5W/cm2 (group A)
Trial: 9862296
Drug: Continuous ultrasound
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ultrasound therapy at 0.8W/cm2 (group B)
Trial: 9862296
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound therapy at 0.0W/cm2 (group C)
Trial: 31006996
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CCT) group